Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers

Purpose: The objective of this study was to evaluate the role of the expression of topoisomerase II, BCL-2, and Ki-67 in an ovarian tissue and their effects on the development and the prognosis of ovarian cancers. Materials and Methods: The study consisted of 38 female patients with ovarian cancers. Patients' characteristics, tumor type, stage, and the grade of the disease, and topoisomerase II, Bcl-2, and Ki-67 values in ovarian tissue were compared. Results: Extensivenesses of topoisomerase II and Ki-67 staining in early-stage disease were found statistically different from those in the advanced stage diseases (for topoisomerase II, 60.38 ± 33.87% vs 85 ± 8.5%, p = 0.017, for Ki-67; 25.07 ± 25.04% vs 51±25.29%, p = 0.012). Differences of Bcl-2 staining between two groups were not significant (30.38 ± 38.82 % vs 18.2 ± 30.58%, p = 0.377). Conclusions: Expressions of topoisomerase II and Ki-67 in ovarian cancer tissues were associated with advanced stage diseases and expression of Bcl-2 refers to good histological grade in patients.

Ovarian cancer; Topoisomerase II; Bcl-2; Ki-67; Cancer tissue.

[1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J.: “Cancer statistics”. CA Cancer J. Clin., 2008, 58, 71.

[2] Disaia P.J., Greasman W.T: “Epithelial ovarian cancer”. In: Disaia P.J., Greasman W.T. (eds). Clinical gynecology oncology. 5thed. St Louis: Mosby, 1997, 282.

[3] American Cancer Society: “Cancer facts and figures”. Atlanta, GA, 1999.

[4] Jacobs I., Bast R.C. Jr.: “The CA–125 tumor-associated antigen: a review of the literature”. Hum. Reprod., 1989, 4, 1.

[5] Bosari S., Moneghini L., Graziani D.: “Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarsinomas”. Hum. Pathol., 1995, 26, 534.

[6] Emi M., Kim R., Tanabe K., Uchida Y., Toge T.: “Targeted therapy against Bcl-2- related proteins in breast cancer cells”. Breast Cancer Res., 2005, 7, 940.

[7] Lauwers G.Y., Scott G.V., Korpeh M.S.: “Immunohistochemical evaluation of bcl–2 protein expression in gastric adenocarsinomas”. Cancer, 1995, 75, 2209.

[8] Ozols R.F.: “Update on Gynecologic Ocology Group (GOG) trials in ovarian cancer”. Cancer Invest., 2004, 22, 11.

[9] Rodes J.: “Hormonal responses to large paracentesis: are discordant results due to technologic differences?” Hepatology, 1990, 11, 1087.

[10] Isola J., Kallioniemi O.P., Korte J.M., Wahlstrom T., Aine R., Helle M., et al.: “Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival”. J. Pathol., 1990, 162, 295.

[11] Kerns B.J., Jordan P.A., Faerman L.L., Berchuck A., Bast R.C. Jr., Layfield L.J.: “Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis”. Am. J. Clin. Pathol., 1994, 101, 192.

[12] Goff B., Ries J., Els L., Coltrera M., Gown A.: “Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure”. Gynecol. Oncol., 1998, 70, 378. 678.

[13] Wong W.S., Tattersall M.H.: “Immunohistochemical determination of tumor growth fraction in human ovarian carcinoma”. Br. J. Obstet. Gynaecol., 1989, 96, 720.

[14] Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K.: “Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers”. Anticancer Res., 1994, 14, 603.

[15] Layfield L.J., Saria E.A., Berchuck A., Dodge R.K., Thompson J.K., Conlon D.H., et al.: “Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis”. J. Surg. Oncol., 1997, 66, 230.

[16] Anttila M., Kosma V.M., Ji H., Wei-Ling X., Puolakka J., Juhola M., et al.: “Clinical significance of alpha-catenin, collagen IV, and Ki–67 expression in epithelial ovarian cancer”. J. Clin. Oncol., 1998, 16, 2591.

[17] Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuireW.P., HoskinsW.J., et al.: “Defining response of ovarian carsinoma to initial chemotherapy according to serum Ca125”. J. Clin. Oncol., 1996, 14, 1545.

[18] Ozols R.F.: “Treatment goals in ovarian cancer”. Int. J. Gynecol. Cancer, 2005, 15, 3.

[19] Noviello E., Aluigi M., Cimoli G., Rovini E., Mazzoni A., Parodi S., et al.: “Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks”. Mutat. Res., 1994, 311, 21.

[20] Huber A.O., Evan G.I.: “Cooperative interaction between c-myc and bcl– 2 rotooncogene”. Nature, 1992, 359, 554.

[21] Özkal S., Tuna B., Koyuncuoğlu M., Selma Ş., Emek Ö., Turhan U.: “Epitelyal over tümörleri ile Bcl-2, nm 23 ve c-erbB-2 ekspresyonları arasındaki ilişki”. Cerrahpaşa Tıp. Dergisi, 2002, 33, 79. [Article in Turkish]

[22] Gotlieb W., Goldberg I., Weisz B., Davidson B., Novikov I., Kopolovic J., et al.: “Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer”. Gynecol. Oncol., 2001, 82, 99.

[23] Brutsmann H.: “Expression of cellular apoptosis susceptibility protein serous ovarian carsinoma: a clinicopathologic and immunohistochemical study” Gynecol. Oncol., 2004, 92, 268.

[24] Chan W.Y., Cheung K.K., Schorge J.O., Huang L.W., Welch W.R., Bell D.A., et al.: “Bcl-2 and p53 protein expression, apoptosis and p53 mutation in human epithelial ovarian cancers”. Am. J. Pathol., 2000, 156, 409.

[25] Bélanger S., Côté M., Lane D., L'Espérance S., Rancourt C., Piché A.: “Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells”. Gynecol. Oncol., 2005, 97, 796.